

In the Claims:

Please amend claims 42 and 56 as set forth below.

1-38. (Canceled).

39. (Withdrawn) A method for promoting angiogenesis in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

40. (Withdrawn) A method for treating a disease or condition characterized by the absence of desired angiogenesis in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

41. (Withdrawn) The method according to claim 40, wherein the disease or condition is selected from the group consisting of: coronary artery disease, wound healing, peripheral vascular disease associated with diabetes, peripheral vascular disease, peripheral artery disease.

42. (Currently amended) A method for treating or preventing a condition or disease characterized by pathological vascular remodeling in a subject in need thereof, said method comprising the step of administering a composition comprising Nogo-B or an amino terminus fragment of Nogo-B that retains a biological activity of Nogo-B.

43. (Previously presented) The method according to claim 42, wherein the disease or condition is selected from the group consisting of: hypertension, restinosis, transplant vasculopathy, arteriosclerosis, ischemia, pulmonary hypertension, asthma, myocardial infarction and cerebrovascular infarction.

44. (Withdrawn) A method for promoting vascular quiescence in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

45. (Withdrawn) The method according to claim 44, wherein the subject suffers from a condition selected from the group consisting of: asthma, hypertension, pulmonary hypertension.

46-48. (Canceled).

49. (Withdrawn) A method for reducing neointima formation in a blood vessel in a subject in need thereof comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

50. (Withdrawn) A method for inhibiting vascular injury-induced vascular narrowing or occlusion in a subject comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

51. (Withdrawn) A method for preventing vascular injury induced ischemia comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

52. (Withdrawn) A method for promoting endothelial cell adhesion, spreading and migration comprising the step of contacting the cell with Nogo-B or a fragment thereof that retains a biological activity of Nogo-B.

53. (Withdrawn) A method for inhibiting vascular smooth muscle cell migration comprising contacting the cells with Nogo-B or a fragment thereof that retains a biological activity of Nogo-B.

54. (Withdrawn) A method for treating a subject suffering from a vascular injury comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B that retains a biological activity of Nogo-B.

55. (Previously presented) The method according to claim 42, wherein the disease or condition is ischemia.

56. (Currently amended) A method for treating a condition or disease characterized by pathological vascular remodeling in a subject in need thereof, said method comprising the step of administering a composition comprising Nogo-B or a fragment of Nogo-B comprising 1-200 of the N-terminus of Nogo-B that retains a biological activity of Nogo-B, wherein said biological activity is selected from the group consisting of promoting endothelial cell adhesion, spreading and migration.

57. (Previously presented) The method according to claim 56, wherein the disease or condition is selected from the group consisting of: hypertension, restinosis, transplant vasculopathy, arteriosclerosis, ischemia, pulmonary hypertension, asthma, myocardial infarction and cerebrovascular infarction.

58. (Previously presented) The method according to claim 56, wherein the disease or condition is ischemia.

59. (Previously presented) The method according to claim 56, wherein the pathological vascular remodeling is in response to an injury.